• By ICR Secretariat
• Posted Tuesday, February 20, 2024

In wake of Reata buyout, Biogen's key launch Skyclarys passes muster in EU

https://www.fiercepharma.com/pharma/less-year-after-biogen-buyout-reatas-would-be-rare-disease-blockbuster-passes-muster-eu

Roughly half a year after Biogen’s $7.3 billion buyout of rare disease specialist Reata Pharmaceuticals, the companies’ blockbuster bid for Reata’s Friedreich’s ataxia (FA) drug Skyclarys is starting to take shape.